Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05031949
Study type Interventional
Source Tongji Hospital
Contact Ze-yang Ding, M.D.
Phone +86-13407156200
Email [email protected]
Status Recruiting
Phase Phase 1
Start date August 31, 2021
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04592029 - TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC Phase 1
Not yet recruiting NCT03283956 - Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan N/A
Recruiting NCT03652467 - The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Phase 1
Completed NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma N/A
Not yet recruiting NCT04965454 - Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma Phase 2
Recruiting NCT04599777 - TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Phase 2
Recruiting NCT04599790 - TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Phase 2
Recruiting NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC Phase 2
Active, not recruiting NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC Phase 2
Recruiting NCT04273100 - PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC Phase 2
Withdrawn NCT03563170 - QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04997850 - The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT03138031 - Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT03881501 - Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
Recruiting NCT03864211 - Thermal Ablation Followed by Immunotherapy for HCC Phase 1/Phase 2
Recruiting NCT04967495 - TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT N/A
Recruiting NCT04967482 - DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC N/A
Recruiting NCT04718909 - Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Phase 2
Not yet recruiting NCT03807947 - Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma N/A
Terminated NCT01009593 - Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) Phase 3